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ABSTRACT 1 
Background: Community pharmacy practice in the Kingdom of Saudi Arabia (KSA) faces many 2 
challenges. In KSA, there is a lack of empirical research about medication safety in this setting.  3 
Objective: To explore the safety problems associated with medication supply from community 4 
pharmacies in KSA and compare different stakeholder perspectives. 5 
Methods: Four focus groups and individual interviews were conducted in Riyadh, KSA, in 6 
February-May 2013. All group discussions were recorded, transcribed and translated from 7 
Arabic into English, except the professional group, which was conducted in English. Thematic 8 
analysis was performed using the Human Factors Framework (HFF).  9 
Results: The groups comprised “professionals” (n=8; one female), community pharmacists 10 
(n=4; all male) and two pharmacy user groups (females, n=11 and males, n=8). Medication 11 
safety problems identified were categorised into nine categories representing the HFF. Seven 12 
main themes were identified from these categories: commercial pressure on community 13 
pharmacy; illegal supply of prescription medication; lack of enforcement of regulations; the 14 
healthcare system; self-medication; patient trust in pharmacists: and communication failure. 15 
Themes that emerged only from the “professionals” and community pharmacists were the 16 
different role of the regulatory organisations and the reasons behind lack of enforcement, while 17 
the community pharmacist group focused on the relationship between owners and managers. 18 
Pharmacy users expressed a need for information about medication and that the primary role of 19 
the pharmacist should be as an information provider. Furthermore, they perceived pharmacists 20 
to be vendors rather than healthcare professionals.  21 
Conclusion: Many medication safety problems were identified, attributable to individuals 22 
(patient, pharmacist), pharmacy and organisational factors. These results will be used to 23 
develop interventions to improve medication safety. 24 
  25 
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BACKGROUND 26 
The World Health Organisation has highlighted safety in primary care as an international 27 
challenge.[1] In primary healthcare, adverse drug events (ADEs) are reported to occur in 25% of 28 
outpatients, almost half of which (11%) are preventable.[2] Research undertaken in the 29 
community pharmacy setting has mostly focused on detecting and measuring medication errors 30 
and near misses.[3]  31 
Studies in the Kingdom of Saudi Arabia (KSA) have shown high levels of hospital admissions 32 
associated with drug-related problems (DRPs), of which the most common causes were ADEs, a 33 
failure to receive medication and medication non-compliance.[4,5] A range of challenges to 34 
medication safety in KSA were identified: limited use of technology; illegal supply of 35 
prescription only medication (POM); communication gaps between healthcare institutions: 36 
under-reporting of ADEs and communication barriers.[6] Studies in KSA have mainly 37 
investigated the problems either from a pharmacist or a pharmacy user perspective using 38 
mostly surveys.[7-11]  No qualitative studies have been conducted with pharmacy users or 39 
other stakeholders, such as policy makers and pharmacy owners. 40 
The application of theory may help to understand patient safety problems and a number of 41 
relevant frameworks exist. [12-17] The Human Factors Framework (HFF) has potential to 42 
enhance clinical performance by understanding the effects of factors such as teamwork, tasks, 43 
equipment, workspace, culture and organisation on human behaviour and abilities, and 44 
applying insights to clinical settings. [14-18] The HFF aids understanding of people’s 45 
capabilities and limitations, allowing design of better systems. It is a recognised tool to reduce 46 
medication error rates or mitigate adverse medication effects. [12]  47 
The purpose of our study was to explore and compare different stakeholder perspectives 48 
regarding the safety problems associated with medication supply from community pharmacies 49 
in KSA using the HFF. The stakeholders for whom medication safety is important include service 50 
users, community pharmacists, pharmacy owners, as well as representatives from legal and 51 
regulatory authorities.  52 
METHODS 53 
This qualitative study comprised a series of focus groups and interviews. Focus groups were 54 
conducted with different stakeholders: healthcare professionals; community pharmacists; and 55 
pharmacy users. Individual interviews were conducted with community pharmacists only. 56 
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Sampling and recruitment  57 
The study was conducted in Riyadh, the capital of KSA. The healthcare professional group (PG) 58 
was recruited purposively, identified through professional and personal networks.  59 
 60 
The community pharmacist group (CPG) was recruited using purposive, convenience and 61 
snowballing methods. Personal visits to pharmacies and telephone calls were made to invite 62 
participants.  Telephone interviews were offered only to community pharmacists who could not 63 
attend the focus group due to job commitments.  64 
 65 
Pharmacy users aged 18 and older were eligible to participate. Different recruitment strategies 66 
were adopted to reflect the cultural constraints in Saudi society.  For the female pharmacy user 67 
group (FPG), community centres and sites for social activities were sought in Riyadh. A non-68 
profit childcare association providing free weekly parenting courses in community centres was 69 
identified, to recruit female attendees who were of various ages and educational backgrounds. 70 
For the male pharmacy user group (MPG), an announcement about a support group for 71 
caregivers of Alzheimer patients was sent via Twitter from the Alzheimer Society account. This 72 
support group is held once a month in a private training centre.  The researcher (LJ) visited one 73 
of these support group meetings for recruitment purposes.  74 
 75 
All potential participants, irrespective of group, received an invitation letter and study 76 
information sheet. A consent form was provided by e-mail or personally, one week prior to the 77 
focus group. Each participant signed an individual informed consent statement prior to the 78 
commencement of the focus groups.  79 
Data collection    80 
The focus groups were conducted using semi-structured topic guides (Supplementary Material) 81 
(one for FPG and MPG and one for the PG and CPG), which were informed by the literature and 82 
the HFF. Data were collected on participants’ age, gender, and education background and 83 
practice experience. The PG was moderated by MW.  The remaining focus groups were 84 
moderated by LJ, with SA in attendance. Before undertaking the group discussions, a pilot focus 85 
group was conducted with first year undergraduate pharmacy students to test questions and 86 
data collection methods. 87 
Research ethics  88 
This study was completed as part of the first author’s PhD thesis who undertook specific 89 
training regarding conducting and analysing qualitative research. Approval for this study was 90 
received from The College Ethics Review Board, University of Aberdeen, UK.  91 
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Data management and analysis  92 
Each focus group was audio-recorded and transcribed verbatim by LJ. The groups were 93 
undertaken in Arabic and the transcripts were then translated from Arabic into English, except 94 
for the PG group, which was conducted in English. A member of the research team (LJ) 95 
undertook the translation; a professional translator checked the accuracy of the translation. The 96 
analysis used a priori and emergent codes; codes were identified independently from the data 97 
by two researchers (LJ, MW). [19] The codes were then categorised using the HFF. Two coding 98 
(Supplementary Material) indices were generated based on commonality of codes: one was 99 
used to code the transcripts of the PG and CPG, while the other was for the pharmacy user 100 
groups. The coding for each focus group was checked for accuracy by a second researcher (MW, 101 
SA, or PK). A comparative analysis was then conducted to identify commonality, differences and 102 
relationships through the themes categorised in the HFF to identify mega themes. [19] This 103 
study was conducted and reported in accordance with COnsolidated Criteria for Reporting 104 
Qualitative Studies (COREQ). [20] 105 
RESULTS 106 
In total, 35 individuals participated across four focus groups and four interviews (Table 1).  All 107 
data collection was undertaken between February and May, 2013. The PG (n=8) comprised 108 
representatives from several organisations responsible for regulating pharmacists and 109 
pharmacy practice, as well as pharmacy academics and pharmacy owners. All participants in the 110 
PG were Saud nationals. The CPG participants were Egyptian (n=3) and Yemeni (n=1).  111 
Table 1 Characteristics of participants 112 
Only males are permitted to work in the community pharmacy setting in KSA. 113 
SD Standard deviation 114 
 115 
The data were categorised into nine categories representing the HFF (Table 2). From these 116 
categories, seven main themes were identified (Table 3). Example of similarities and differences 117 
of themes across all groups are presented in (Table 4). The themes are described in the text 118 
 Professionals  Community 
pharmacists 
Pharmacy users 
Focus Groups  Focus group Focus 
group 
Individual  
Interviews 
Female 
focus group 
Male focus 
group 
Total Individuals invited  15 75 5 15 9 
Number of participants 
(male) 
8 (7) 4 (4*) 4 (4*) 11 (0) 8 (8) 
Age years (SD) 
40.6 (7.1) 
34.7 
(10.6) 
37.7 (13.8) 33.5 (5.8) 34 (5.9) 
Duration of interaction 
(minutes)  104 86 
 
19.2 (3) 
Mean (SD) 
62 89 
5 
 
supported by anonymised, verbatim quotes from participants’ narratives (which are written in 119 
italics and quotation marks). To illustrate which focus group generated the identified themes, 120 
results are referred to below by the following letters: professionals (PG); community 121 
pharmacist (CPG); female pharmacy users groups (FPG) and male pharmacy users groups 122 
(MPG), followed by a hyphen and the number of the participant, e.g. PG-1 is participant 1 in the 123 
PG, etc. For further quotes in the Supplementary Material.  124 
Table 2 Human Factors and sub-themes identified in the Focus groups 125 
Human factors category Sub-themes 
External factors Commercial pressure and commercialism  
Regulations and regulators  
The healthcare system in Kingdom of Saudi Arabia  
Organisational and 
management factors 
Pharmacy owners’ and managers’ roles 
Lack of patient database in community pharmacies 
Work environment Pharmacist working hours 
Type of pharmacy and its effect on medication safety 
Team factors Physician prescribing behaviour  
Communication between pharmacists and physicians  
Individual factors: 
Pharmacists 
Pharmacist competence and clinical skills 
Pharmacist adherence to law and regulations 
Pharmacist role as perceived by participants 
Task factors Illegal Supply of prescription-only medication to patients. 
Medication storage and transportation in community pharmacies 
Generic substitution 
Communication and 
information exchange 
Patient–pharmacist communication 
Factors affecting communication exchange 
Type of information requested by patients from pharmacists 
Patient medication information source  
Pharmacist versus physician information 
Patient Patient characteristics: risk factors for medication safety problems 
Patient trust in pharmacists 
Patient trust in physicians 
Patient beliefs and perceptions 
Patients’ behaviour 
Patient role and responsibility towards medication safety 
Medication Medicines associated with the risk  
Medication availability and shortage  
Counterfeit medication 
Others Patient experiences with drug–drug interaction and adverse drug events 
Comparison with other countries regarding practice and quality of 
medication. 
 126 
 127 
 128 
 129 
 130 
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Table 3 Emergent themes identified 131 
Emergent themes Sub-themes 
Commercialism and 
commercial pressure on 
community pharmacies in 
kingdom of Saudi Arabia  
External factors 
• Commercial pressure and commercialism  
• Healthcare system role in commercialism 
Organisational and management factors  
• The role of pharmacy owners and managers  
Work environment  
• Type of pharmacy and its effect on medication safety 
• Pharmacist working hours 
• Low salaries  
Team factors 
 Physician prescribing behaviour  
Task factors  
 Patient counselling  
 Generic substitution 
 Medication storage and transportation 
Patient factors 
 Patient belief and perception about the business oriented 
practice 
 Patient behaviour 
Illegal supply of 
prescription medication 
by pharmacist 
External factors 
Individual factors: pharmacist  
Patient factors 
Lack of enforcement of 
regulations  
External factors 
• Regulations and regulators 
Individual factors: pharmacist  
• Pharmacist adherence to law and regulations 
Patient factors 
• Patient pressure on pharmacists to commit a misconduct 
Medication 
 Counterfeit medication as consequence  
Healthcare system in 
kingdom of Saudi Arabia  
External factors  
• The fragmented healthcare system 
• Lack of patient database in community pharmacies 
Organisational and management factors  
 Implementation of technology in community pharmacy 
Patient medication-taking 
behaviour 
• Self-medication 
• Sharing medication 
• Adherence to medication 
Patient trust in 
pharmacists 
No subthemes identified 
Communication and 
information exchange  
• Patient–pharmacist communication 
• Patient medication information source  
• Factors affecting communication exchange 
• Type of information requested by patients from pharmacists 
• Information received from pharmacist information compared to 
information received from physician  
Team factors 
• Communication between pharmacists and physicians 
 132 
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Table 4 Example of similarities and differences of themes across all groups 133 
 
Theme 
 
Professionals 
 
Pharmacists 
Pharmacy users 
Male Female 
Commercialism and commercial pressure 
on pharmacists. 
✔ ✔ ✔ ✔ 
Self-diagnosing and self-medication.  ✔ ✔ ✔ ✔ 
Lack of enforcement of regulations. ✔ ✔ ✔ ✔ 
Illegal supply of prescription medication.  ✔ ✔ ✔ ✔ 
Fragmented healthcare system. ✔ ✔ ✔  
Patient trust in pharmacist.  ✔ ✔ ✔ 
The primary role of the pharmacist should 
be as an information provider.  
 ✔ ✔ ✔ 
Communication failure between 
pharmacists and patients. 
✔ ✔   
The need for information   ✔ ✔ 
Perception of pharmacists as salesmen 
rather than healthcare professionals.  
  ✔ ✔ 
Pharmacy design and its effect on 
counselling.  
  ✔ ✔ 
 134 
Commercialism and commercial pressure 135 
Commercialism in community pharmacy practice in KSA emerged as a theme in all groups. 136 
Participants identified factors and consequences of commercialism on patient safety. These 137 
factors are presented here according to the HFF: external; organisational; work environment; 138 
team; task; and patient factors. 139 
External factors 140 
Participants across all groups except the FPG discussed the role of pharmaceutical companies in 141 
creating commercial pressure by paying bonuses to physicians and community pharmacists to 142 
prescribe and dispense certain medications, which may not be needed.  143 
“In our country, the pharmacist gives you the medication that is suitable to him 144 
or the medication for which he receives a commission, you go to the pharmacist 145 
you say you have a headache he gives you Fevadol instead of Panadol [generic 146 
substitute] for example he gives you the medication that suits you, who he is an 147 
agent for it or gives him a commission for. Even in clinics, the representative of 148 
the company comes to the physician and gives him the new medications with 149 
tickets and gifts and the physician prescribes the medications.”  (MPG-5) 150 
The PG participants suggested that recent rapid increases in the number of pharmacies, 151 
combined with their proximity to each other, contributed to increased competition between 152 
8 
 
them.  This pressured pharmacists to illegally supply POM to to maintain their business and 153 
retain consumers/patients. 154 
 “It is not logical that I will not sell the medication without [prescription], while my 155 
neighbour is selling it without [prescription]. I would go broke.” (PG-2)  156 
The PG participants also suggested that the pharmaceutical industry restricted certain generic 157 
medicines to increase sales of newer, more expensive brands, contributing to medication 158 
shortages.  159 
“I comment on availability issues. Some of it [is] truly shortages, and some of it is 160 
[not]. Unfortunately, this is a commercial business. I know some pharmacies will 161 
not introduce a product without getting fees or getting huge bonuses from the 162 
company. The company will not be able to sell it that is again with the law how far 163 
you can enforce the law on community pharmacy?”  (PG-4) 164 
 165 
Organisational and managerial factors  166 
Participants in the CPG believed that pressure from owners and managers of community 167 
pharmacies contributed to creating a profit-oriented rather than patient-oriented pharmacy 168 
practice.  169 
“Maybe he is being pushed by his managers to be money making…” (MPG-3) 170 
Work environment  171 
The CPG, FPG and MPG perceived community pharmacies owned by commercial companies 172 
(also known as chain pharmacies) to be safer than independent pharmacies. They explained 173 
that chain pharmacies have more rigorous internal regulatory systems, offer training 174 
programmes for the pharmacists and have lower individual workload owing to investment in 175 
technology. Interestingly, the public group believed that independent pharmacies are less 176 
affected than chain pharmacies by commercial pressures.   177 
 178 
“[Chain pharmacies] have a policy that we will not violate the law and the 179 
patient will find what he wants; this is the mistake of the patient” (CPG-1) 180 
 181 
The CPG and MPG participants discussed long working hours and their effect on practice. They 182 
believed that the long working hours were related to the owner’s interest in maintaining their 183 
profit. 184 
“He has long working hours and that leads many pharmacists to not refresh 185 
their information, …there is no role for the Ministry to update your 186 
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information. For example, the pharmacist (CPG-4) graduated in 1986 and 187 
necessarily many improvements have taken place since that time.” (CPG-2) 188 
 189 
Team factors 190 
The PG also acknowledged that pharmaceutical companies influence the prescribing behaviour 191 
of physicians through advertising and financial incentives, which tends to result in 192 
overprescribing.  193 
“The quality of the physician usually they come with very low salaries but 194 
depending on the commissioning they get from the companies and still they have 195 
the commission we see the kind of prescription which is very weak even our 196 
pharmacists discover these mistakes it happens with me a lot so due to this kind of 197 
this low educated physicians.” (PG-2) 198 
Task factors  199 
Participants in the pharmacy user groups felt that commercial pressure on pharmacists affected 200 
the advice and information provided. They suggested that advice given by the community 201 
pharmacists was for marketing purposes and not tailored to patients’ actual needs. 202 
“My problem is always that when I go, they give me the best and the latest on the market, 203 
that is to say, they do not give me the one appropriate for me. The problem is that they do 204 
not try to learn whether it is appropriate or not.” (FPG-1) 205 
 206 
Pharmacists substituting a prescribed branded medication with a different form of the same 207 
active substance (generic substitution) was an emerging theme across all groups.  The PG stated 208 
that the problem is that community pharmacists provide medication alternatives to patients 209 
based on financial incentives and commission rather than patient benefit.  210 
“If you go to a pharmacist and you say you have a mild or minor ailment and 211 
ask for a prescription, you have two products [options] one product will fit you, 212 
but that does not have a bonus, the other product has a bonus.” (PG-4) 213 
 214 
Participants discussed the problem of inappropriate storage conditions for medicines in 215 
community pharmacies and warehouses, attributed by some participants in the PG and 216 
pharmacy users’ groups to a desire to cut costs.  217 
“It is a matter of saving electricity just like groceries. At night, they disconnect 218 
the refrigerator containing milk to save electricity, and when they come back 219 
in the morning, they turn on the electricity.”   (MPG-4) 220 
 221 
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Patient factors 222 
On a number of occasions, participants in the PG as well as the pharmacy user groups referred 223 
to the way that patients perceive the community pharmacy as a grocery shop.  224 
“We look in KSA at a pharmacy as a store … It should be a service, not a store.” 225 
(PG -3) 226 
However, perceptions of pharmacists were highly varied amongst participants in the pharmacy 227 
user groups. Some considered pharmacists to be salesmen, while others perceived them as 228 
healthcare professionals.  229 
“He is interested mainly in collecting money.” (FPG-3) 230 
 231 
“People think that he is a seller, but he is well qualified in term of education. He 232 
spent a long time studying and understands drug composition maybe more than 233 
the physicians.” (FPG -2) 234 
Participants in the pharmacy user groups acknowledged that they buy whatever they want from 235 
the pharmacy acting as a “consumer.” 236 
“As a consumer, I go to the pharmacy and take the antibiotic I want, I can take 237 
whatever medication I want without prescription.”  (MPG-5) 238 
 239 
Illegal supply of prescription medication by pharmacists  240 
External factors  241 
The PG suggested many reasons to explain the illegal supply of POM which they described as a 242 
violation of regulations, including patients perceiving medication as a commodity and patients 243 
who are stable on medication visiting the community pharmacy to refill their POM without a 244 
prescription. In addition, they suggested other “external factors” that were highlighted 245 
previously, such as the limited capacity of the healthcare system, the lack of regulation 246 
enforcement and commercial pressures.  247 
“…So now you have lack of enforcement of the law, huge pharmacies, huge 248 
number of non-Saudi pharmacists and you can say there is nobody in charge 249 
that lead to where people are treating medications as a commodity rather 250 
than special products that need attention…” (PG-4) 251 
 252 
However, such practices were identified as a cause of hospital admission by the PG. Antibiotics 253 
were given as an example of medication supplied illegally in all groups, and participants in the 254 
CPG provided other examples, such as hypnotics and antidepressants.   255 
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Individual factors: pharmacists  256 
Participants in the CPG acknowledged that they sometimes illegally supply POM and provided 257 
justifications for their actions.  258 
“I dispense everything; I am a pharmacist regardless of the laws, when you have a 259 
patient in front of you needing to be treated it would be difficult especially if the 260 
patient is poor and needs assistance you do not help him; for humanity” (CPG-4) 261 
 262 
Lack of enforcement of regulations  263 
Lack of enforcement of regulations emerged as a theme in all groups. Factors and consequences 264 
of lack of enforcement of regulations identified in this study are presented in this section 265 
according to the HFF: external; pharmacist and patient. 266 
External factors  267 
Across all groups, participants agreed that the Saudi government issued regulations to uphold 268 
the quality of community pharmacy practice. Participants also identified the roles played by 269 
different regulatory bodies in inspecting and controlling medication supply. However, they all 270 
agreed that governmental regulations are not enforced effectively.  271 
  “…There is a complete difference between the law and the reality.”  (CPG-2)   272 
 273 
The PG suggested that there were too few governmental inspectors in relation to the large 274 
number of community pharmacies. Furthermore, the community pharmacists perceived 275 
inspectors to be inadequately trained.  276 
“...The number of inspectors who are supposed to enforce the law have almost 277 
declined you don’t have the same growth in the number of inspectors as you have in 278 
the number of the pharmacies...so that automatically leads to the lack of enforcement 279 
of the law so now you have lack of enforcement of the law, huge pharmacies, huge 280 
number of expatriates pharmacists and you can say there is nobody in charge.”  (PG-281 
4) 282 
 283 
Individual factors: pharmacists  284 
Pharmacists’ adherence to regulations emerged during the discussion. One participant in the PG 285 
group believed that all pharmacists would like to adhere to the law. 286 
                        “No professional pharmacist will like to break the law...” (PG-4)   287 
 Conversely, the CPG admitted violating certain pharmacy practice regulations. There were 288 
examples of pharmacist violations given in all the focus groups, such as illegal supply of POM, 289 
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inappropriate storage conditions of medication, pharmacists working without licence, and 290 
supplying medication without a label.  291 
“The air conditioning is not working, the expiry date of the medicine … also they store 292 
medicines outside the refrigerator.  We found some big problems we saw the 293 
technician dispensing the medicine they are not allowed to dispense the medication 294 
also find the pharmacist work without licence this is a big problem in the pharmacy.” 295 
(PG-8) 296 
 297 
Patients factors  298 
Patients also influence pharmacists’ behaviour in terms of not adhering to regulations due to 299 
pressurising pharmacists to illegally supply medications. Participants in the CPG said that they 300 
find themselves compelled to supply medication to patients in these situations, despite this 301 
being prohibited by law. 302 
“Originally, it is prohibited by the Ministry of Health to dispense antibiotic as a 303 
strip and if this is done it would be a violation and in case of not dispensing them in 304 
this form, the patient will go to a second, third and fourth pharmacy until he finds 305 
what he wants” (CPG-1) 306 
 307 
The healthcare system in Kingdom of Saudi Arabia  308 
Participants in all groups discussed factors related to the healthcare system and their impact on 309 
medication safety in Saudi Arabia.  These factors are presented here according to the HFF: 310 
external and organisational factors. 311 
External factors 312 
The structure of the Saudi healthcare system was an emerging theme. The PG and FPGs 313 
discussed the fragmented healthcare system.  Patients visiting different physicians for the same 314 
medical problem and a lack of continuity in care are the results of the fragmented provision of 315 
healthcare that could lead to medication duplication and compromised medication safety.  316 
“For example, the patient went to a physician who prescribed him Amlor 317 
[Amlopidine] and then went to another physician who prescribed him Amlopine 318 
[Amlopidine]. He imagined that they are different medications and took both.”  319 
(CPG-4) 320 
 321 
The PG discussed the limited capacity of the healthcare system and its inability to meet the 322 
increasing healthcare needs of the population. They suggested that community pharmacies 323 
could play a role in caring for patients to minimise the pressure on other healthcare facilities.  324 
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“Community pharmacy should work as primary centres … take for example diabetic 325 
patient whatever the government invest and put amount of money in hospitals and 326 
primary care they will not be able to manage the whole diabetic population. They are 327 
huge [the diabetic population] so if you add hypertensive patients and asthmatic 328 
patient they are huge.” (PG-4) 329 
 330 
Participants also discussed the lack of a patient database and filing system in community 331 
pharmacies: they perceived an electronic patient database with relevant medical information 332 
accessible to community pharmacists to be an important factor in medication safety.  333 
“There should be a special file for each patient in each pharmacy, not only in the hospital.” 334 
(CPG-1) 335 
 336 
Organisational and management factors 337 
Participants suggested that solving the problem starts with the Saudi Ministry of Health, which 338 
should establish a national electronic health records database. The need to implement 339 
technologies such as electronic prescribing and to utilise drug information software, was 340 
discussed in both the PG and the CPG.  341 
Patient medication taking behaviour  342 
Patients’ accounts of behaviours such as self-medication, sharing medication and adherence to 343 
medication emerged. Self–medication in the context of this study is the selection and use of 344 
medicines by individuals to treat self-recognized conditions or symptoms with POM or over the 345 
counter (OTC) medication. Participants in all groups agreed that self-medication is common in 346 
KSA.  347 
“I went to the pharmacy and said [something] and then some medications were 348 
given to me, that is, we are treating ourselves.” (MPG-1) 349 
  350 
The MPG proposed several reasons for self-medication such as cultural influences, the 351 
accessibility of medication, the large number of community pharmacies, and patients’ previous 352 
experiences with a medication.  353 
The CPG highlighted that patients even self-medicate with antidepressants without consulting a 354 
physician. They were also aware of medication abuse such as the use of steroids for weight gain 355 
and skin whitening.   356 
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“Most people request Seroxa [antidepressant], and a segment of women take it due 357 
to marriage pressures. They take psychiatric medicines as a tonic that enables them 358 
to deal with the community in a better way.” (I-3) 359 
 360 
Sharing medication emerged as a theme across the CPG, FPG and MPG. Participants discussed 361 
sharing medication such as vitamins, painkillers and antibiotics with family members: “As fruits 362 
in the refrigerator.” (MPG-5)  363 
“Sometimes I think that the factor is economics and he doesn’t want to pay for 364 
something he doesn’t want to continue using.” (CPG-1) 365 
 366 
 Patients do not adhere to their medications and do not follow instructions provided by 367 
pharmacists as participants in the CPG and MPG described.  368 
“frankly, I never completed the period of the course” (MPG-3) 369 
 370 
The patient’s role in medication safety was discussed in all groups, and there was general 371 
agreement of the importance of educating patients. 372 
Patient trust in the pharmacist  373 
Patient trust in the pharmacist emerged in the CPG and pharmacy user groups.  Participants in 374 
the pharmacy user groups identified several factors that affect this trust, such as pharmacists’ 375 
age, an existing relationship with the patient, provision of advice, pharmacist nationality, and 376 
knowledge of the sector in which the pharmacist worked, e.g. governmental or private. Some 377 
participants perceived pharmacists having low levels of competence due to their non-Saudi 378 
nationality, especially regarding recognising trade names of medication. Another reason for lack 379 
of trust was due to the perception that pharmacists are business-oriented rather than patient-380 
oriented.  381 
“He has knowledge; he is old and calm, and he knows that I am coming for a 382 
consultation. I tell him the physician prescribed this and this. He knows me, and I 383 
buy some of the things. He knows my face, and he counsels me and gives me some of 384 
his time. He says, 'no this is that and this is good', and he gives me alternatives. He 385 
gives me advice. He is next to my home, and I trust his opinion.”  (MPG-4)  386 
 387 
There was disagreement in the MPG that providing generic alternatives increases patients’ trust 388 
in pharmacists. Participants in the CPG identified several factors that cause patients to lose 389 
confidence in the pharmacist.  For example, when the pharmacist spends more time reading the 390 
prescription due to bad physician handwriting or incomplete patient information, which leads 391 
pharmacists to ask the patient more questions. The CPG believed that patients trust physicians 392 
more than pharmacists. 393 
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“I may receive a prescription in which the age and the diagnosis are not mentioned 394 
and what is only mentioned is the name. In order to dispense the medication, I ask 395 
many questions, I ask until I know the meant medication. Asking many questions 396 
results in the loss of confidence between the patient and me. My questions are 397 
meaningful since I concentrate on certain points.” (CPG-3) 398 
Communication and information exchange  399 
Pharmacy users and the CPG discussed poor communication between pharmacists and patients, 400 
including the question of who should initiate communication.  401 
“What I notice is that they take the prescription and put it on the counter, and that is 402 
all. They do not even say hello.”  (MPG-1) 403 
 404 
Pharmacy users expressed a need for information about medication and that the primary role of 405 
the pharmacist should be as information provider. 406 
Barriers to effective communication identified by participants in all groups included language, 407 
culture, education, gender, having a third person (family member or friend) assigned by the 408 
patient to obtain the medication from the pharmacy, pharmacy layout and pharmacists’ 409 
workload.  410 
“I came across someone who didn’t know whether the medication was for 411 
constipation or diarrhoea. He said he wanted something for diarrhoea. The 412 
matter is that he didn’t want something for diarrhoea; he wanted something to 413 
cause diarrhoea. In brief, language has an effect.”  (CPG-4) 414 
 415 
The CPG suggested that patients’ ability to access medication information from other sources, 416 
such as the internet or friends, and the role of TV advertising, can cause problems when 417 
communicating with a patient, as they come to the pharmacy influenced by information from 418 
these different sources.  419 
 “Patients come to me and say, 'I read that this drug is dangerous'. I ask him, 420 
‘Where did you read that?' and he says, 'The internet'.” (CPG-3) 421 
 422 
The CPG also expressed concerns about the patient providing incomplete information or 423 
wrongly expressing symptoms to the pharmacist.The PG and MPG agreed on the need for clear 424 
and easily comprehensible information about medication in Arabic.  425 
DISCUSSION 426 
The study identified a range of major medication safety problems in community pharmacy in 427 
KSA from a range of perspectives. The factors and circumstances that contribute to these 428 
problems are complex and interact with each other.   429 
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Commonalities existed across groups, and unsurprisingly the PG identified problems at a 430 
systemic or regulatory level. For example, all groups discussed the lack of enforcement of 431 
regulations. The professionals provided the reasons behind this, debating the role and 432 
importance of each organisation involved in pharmacy practice. The community pharmacists 433 
discussed the day-to-day problems that pharmacists face in terms of owners, patients and 434 
inspectors. The FPG, of whom the majority were mothers, shared their personal experiences 435 
with pharmacists and medications in their daily lives. The MPG also focused on regulations and 436 
systems and compared current practice in KSA with other countries, such as the UK and USA.  437 
Most studies of medication safety in community pharmacy have considered only one aspect of 438 
safety, such as dispensing  [21], prescribing errors  [22-24] or workload  [25]. Two studies have 439 
adopted holistic approaches to identify medication safety problems. [26,27] Phipps et al., 440 
identified a number of social technical factors consistent with our findings, such as regulatory 441 
and legal factors, group norms, trust in pharmacists, profitability versus safety, quality 442 
assurance and workspace, and collaboration between prescribers and patients. [27] 443 
Commercialisation of pharmacy practice in this study was attributed to corporatisation, 444 
increased numbers of pharmacies, the absence of any governmental reimbursement and the 445 
lack of enforcement of regulations by regulatory bodies. Subsequently, some pharmacists 446 
illegally supply POMs, supply unnecessary medication or provide generic substitution based on 447 
profit not patient benefit. Community pharmacies generally operate as private businesses, thus 448 
the financial impact of any decisions made by community pharmacists is a concern that could 449 
potentially influence the attitude of pharmacists to service provision, for example the reporting 450 
of errors. [27] The Saudi pharmaceutical sector is the largest in the Gulf region, and has recently 451 
been growing by 4.7% annually. [28] There has been a six-fold increase in the number of 452 
community pharmacies in KSA over the past 30 years. [29] This huge market tends to promote 453 
the ‘corporatisation’ of pharmacies, as has happened in the UK, in which there is a change in 454 
ownership pattern from individuals to larger pharmacy chains. [30,31] Bush et al. describe the 455 
impacts – often negative - on the professional autonomy of pharmacists working in these big 456 
companies. [30]  457 
This current study suggests that failure to enforce regulations creates an environment in which 458 
violations become routine practice. For example, lack of enforcement of regulations has been 459 
attributed in this study and others conducted in KSA to the illegal supply of POM. [7-10] There is 460 
a lack of studies exploring the association between violations in community pharmacy practice 461 
and enforcement of regulations. [32] Lowe and Montagu  [33], reviewed regulatory frameworks 462 
in 24 low-income countries and many of the challenges described are similar to those identified 463 
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in this study, particularly in terms of fragmented pharmacy legislation and regulation, and 464 
insufficient numbers of inspectors. [33] Two randomized intervention studies reported the 465 
effect of enforcement of regulation on pharmacist compliance to regulations and improving 466 
services such as giving advice to customers and a decrease in the illegal supply of some 467 
medications. [34,35] 468 
Self-medication was identified in this study as one factor contributing to medication safety in 469 
community pharmacy. Patients who self-medicate usually diagnose and treat themselves based 470 
on their own experience or that of family or friends, or information from the media and internet. 471 
One reason for self-medication identified here was that patients could not afford or wanted to 472 
avoid a physician visit. The main risks from self-medication identified previously include 473 
misuse, a potential delay in treating a serious condition, masking of symptoms of a serious 474 
condition through the use of a OTC medication, and drug interaction. [36,37] It is a cause for 475 
concern that most of the risks previously identified relate to self-medication with OTC 476 
medication, while self-medication with POM is present in KSA. [38]  477 
Another important factor identified is the fragmented healthcare system in KSA. Healthcare 478 
delivery in KSA occurs in ‘mixed market’ systems, with care delivered both by government and 479 
private sector providers. [39,40] This allows patients to obtain healthcare from multiple 480 
healthcare providers, which has been associated with a number of medication safety problems, 481 
including duplicate interventions  [41], multiple prescriptions, exposure to potential drug 482 
interactions  [42], and high costs for patients and the government. [43,44] Given there are no 483 
patient medication records in Saudi community pharmacies, pharmacists will supply the 484 
prescribed medication to patients not knowing their other medication, potentially leading to 485 
medication duplication due to multiple prescriptions from multiple doctors.  486 
The illegal supply of POM has been reported in many developing countries such as Mexico, 487 
China and also in other countries in the Middle East. [45-47] The main reasons identified in KSA 488 
were financial interests and the lack of enforcement of regulations. [7,8,11] Pharmacists in this 489 
current study admitted to the illegal supply of POM and provided several justifications, which 490 
were similar to findings from a qualitative study in India [48], that illegal supply of POMs is a 491 
form of “social work” to help poor patients who cannot afford a physician’s visit. The Indian 492 
study also cited commercial interest and the lack of pharmacist knowledge as reasons for this 493 
behavior.[48] 494 
The lack of communication between pharmacists and patients was identified as a medication 495 
safety problem. The importance of establishing two-way communication in identifying [49] and 496 
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preventing ADEs [50,51] has been previously documented.  497 
An important determinant in establishing a relationship with a pharmacist identified in this 498 
study is trust in the pharmacist.[52] Participants were suspicious of pharmacists’ motives and 499 
their interest in profit rather than patient care. This is consistent with the findings of a study in 500 
Ireland. [53]  501 
Strategies to target these factors and develop systems that ensure safe use of medication within 502 
community pharmacies are needed at different levels.   503 
Strength and limitations of the study 504 
The study findings identified several categories of HFF that are relevant to the community 505 
pharmacy setting and provide a deeper understanding of community pharmacy practice, 506 
including reasons for specific behaviours, such as the illegal supply of POM. Another strength of 507 
the study is that all stakeholders were represented except general medical practitioners. 508 
KSA is socially and culturally unique. As such, some factors identified in the current study may 509 
not apply elsewhere. However, many factors identified are likely to have resonance in many 510 
countries, for example pharmacist workload. [25] The number of participants in the CPG was 511 
small, due to the long working hours of community pharmacist. Supplementary telephone 512 
interviews helped to achieve data saturation; no new themes emerged in the telephone 513 
interviews. [54]  514 
Participants were recruited from Riyadh, the capital of KSA, and opinions might not represent 515 
those of people across KSA. For example, problems relating to non-Arabic speakers may not be 516 
present in more rural areas. More than six million people live in Riyadh, 40% of whom are non-517 
Saudi; this percentage is not the same in other regions. [55] Lastly the majority of participants 518 
had a college education, so less educated individuals were under-represented.  519 
CONCLUSION    520 
Community pharmacy has been shown in this study to be a complex system involving many 521 
interacting factors that influence medication safety. These factors were identified and 522 
categorised using the Human Factors Framework. Commercial pressures on the community 523 
pharmacy sector and community pharmacists, a failure to enforce regulations, the fragmented 524 
healthcare system and self-medication, are all factors that contribute to medication safety 525 
problems. Strategies are needed at different levels to target these factors and develop systems 526 
that ensure safe use of medication within community pharmacies.  527 
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 Supplementary material 687 
Appendix A 688 
Topic Guide for focus group (Pharmacy user’s) 689 
 690 
Questions to be addressed during the focus group 691 
a. What does medication safety mean to you? 692 
Probes: Your personal experience of problems (adverse effect reactions) 693 
b. What medicines are safe? 694 
Probes: Why do you think they are safe? 695 
Probes: when you are familiar with a medicine does this makes it safe? How is that?  696 
c. What medicines do you think are associated with risk? 697 
Probes: Why do you think they are unsafe? 698 
d. What medical conditions are most likely to cause problems with medicines? 699 
e. What patients are most at risks from medication? 700 
Probes: Age, Gender, pregnant women, lactating women, etc 701 
f. What are the main problems that you can encounter in a community pharmacy in 702 
terms of medication safety? 703 
g. How could community pharmacists help people with their medicines? 704 
Probes: your suggestions 705 
h. Any comments 706 
 707 
 708 
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Topic Guide for focus group (Professionals) 709 
 710 
Questions to be addressed during the focus group 711 
a. What are the main medication safety concerns associated with medicines supplied 712 
from community pharmacies in Saudi Arabia? 713 
Probes: Identify the problems and give examples from their point of view and experience. 714 
b. Who are the patients most at risk from medication safety problems? 715 
Probes: what are the medical conditions that have the highest risk to the patient? 716 
Probes: who are the population who are at most risk (age, gender, etc)? 717 
c. What types of medication are associated with safety problems in community 718 
pharmacy? 719 
d. What are the factors that contribute to these problems? 720 
e. How can community pharmacists prevent and manage these problems? 721 
f. What other agencies, organisations could help to improve medication safety with 722 
medicines supplied from community pharmacies? 723 
Probes: How could this is achieved?  724 
g. Any other comments 725 
 726 
 727 
 728 
 729 
 730 
 731 
 732 
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Appendix B 733 
Coding index (expert and community pharmacist) 734 
1. New prescription 735 
1.1 Refill of a prescription medication 736 
1.1.1 With a prescription 737 
1.1.2  Without a prescription 738 
1.2 Self–medication 739 
1.2.1  Internet 740 
1.2.2  TV/ Advertisement 741 
1.2.3 Family, Friends, neighbours 742 
1.2.4 Based on previous experience 743 
 744 
2. Medication use process 745 
2.1 Prescribing  746 
2.1.1 Prescriber 747 
2.1.1.1 Lack of knowledge 748 
2.1.1.2 Failure to communicate between pharmacist and prescriber 749 
2.1.1.3 Unethical prescribing practices/violation of the law   750 
2.1.2 Prescription 751 
2.1.2.1 Prescription incomplete information or ambiguous 752 
2.1.2.2 Handwriting 753 
2.1.2.3 Prescribing error  754 
2.2 Dispensing  755 
2.2.1 Patient pressure to supply medication 756 
2.2.2 Incomplete patient information 757 
2.2.2.1 Patient medical history 758 
2.2.2.2 Medication record  759 
2.2.3 Dilemma between patient care and money (commercial pressure) 760 
2.2.4 Labelling 761 
2.2.5 Illegal supply of medications 762 
2.2.5.1 Factors that contribute to illegal supply of medication 763 
2.2.5.2 Common medications supplied without a prescription  764 
2.2.5.3 consequences of supplying medication without prescription 765 
2.2.6 Generic substitution 766 
2.3 Pharmacist-patient communication 767 
2.3.1 Language 768 
2.3.2 Literacy 769 
2.3.3 Cultural considerations 770 
2.3.4   Third party communicating patient information (family member or  771 
2.3.5 Inaccurate information (self-diagnosis) 772 
 773 
2.4 Administration (Medication taking behaviour) 774 
2.4.1 Sharing medication 775 
2.4.2 Adherence 776 
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2.4.3 Drug abuse 777 
2.4.4 Drug misuse 778 
 779 
2.5 Monitoring  780 
2.5.1 No follow up 781 
2.5.2 Reasons for no follow up 782 
2.5.2.1 No computer system  783 
2.5.2.2 Others  784 
 785 
3. Medication  786 
3.1 High alert medication 787 
3.1.1 Analgesics 788 
3.1.2 NSAIDS 789 
3.1.3 Antibiotics  790 
3.1.4 Cortisone 791 
3.1.5 Control medication 792 
3.1.6 Psychotherapeutic agents 793 
3.1.7 Thyroxine 794 
3.1.8 Weight management agents 795 
3.1.9 Minoxidil 796 
3.1.10 Vitamins 797 
3.1.11 Hormonal replacement therapy 798 
3.1.12 Warfarin 799 
3.2 Other related medication problems  800 
3.2.1 Medications with unimproved indications 801 
3.2.2 Look alike, sound like medications 802 
3.2.3 Counterfeit medications 803 
3.2.4 Expiration date 804 
3.2.5 Bar coding 805 
3.2.6 Pricing 806 
3.2.7 Medication shortage and availability  807 
 808 
3.3 Herbal medication 809 
3.4 Medication distribution 810 
3.4.1 Transportation  811 
3.4.2 Storage  812 
3.5 Medication related problem concerning patient outcome 813 
3.5.1 Duplication of therapy 814 
3.5.2 Adverse drug effects  815 
3.5.3 Dosage regimen 816 
3.5.3.1 Dose to high 817 
3.5.3.2 Dose too low 818 
3.5.4 Drug interaction 819 
4. Patient  820 
4.1 Patient at risk of medication safety problems 821 
4.1.1 Patient with chronic diseases  822 
4.1.2 Patient with Allergies 823 
4.1.3 Patients with poly pharmacy 824 
4.1.4 Gender 825 
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4.1.4.1 Female 826 
4.1.4.2 Male   827 
4.1.5 Age  828 
4.15.1 Paediatric 829 
4.15.2 Geriatric 830 
4.1.6 Education  831 
4.1.7 Language  832 
4.1.8 Patients with no insurance  833 
4.2 Patient /public awareness of medication safety  834 
4.3 Patient perception and attitude towards healthcare professional roles  835 
4.3.1  Physician  836 
4.3.2  Pharmacist   837 
5 Pharmacist  838 
5.1 Scientific knowledge of pharmacist 839 
5.2  Continuing education/ training  840 
5.3 The quality of practice/unprofessional practice 841 
5.4  Nationality 842 
5.5 Pharmacist assessment/ licensing  843 
5.6 Working hours 844 
5.7 Stress  845 
5.8 Fatigue  846 
5.9 Salary 847 
5.10 Pharmacist perception of their role 848 
5.10.1 Compounding  849 
5.10.2 Providing clinical services 850 
5.10.3  Other  851 
6 Pharmacy  852 
6.1 Reimbursement  for pharmacy 853 
6.2 Specialised pharmacy for each population (disease) 854 
6.3 Type of pharmacy  855 
6.3.1 Independent 856 
6.3.2 Chain pharmacy 857 
6.4 Location ,distribution and number 858 
6.5 Pharmacy owners/managers 859 
6.6 The use of technology  860 
6.6.1 Patient databases  861 
6.6.2 Drug information software’s 862 
7 Organisations and systems  863 
7.1 Regulators 864 
7.1.1 Role of the Ministry of Health 865 
7.1.2 Role of Saudi Food and Drug Authority 866 
7.1.3 Role of other organisations  867 
7.2 Role of Universities 868 
7.3 Pharmaceutical companies and manufactures 869 
7.4 Accreditation 870 
7.5 Punishing and rewarding system 871 
7.6 International Organization for Standardization 872 
7.7 Regulation for pharmacy practice 873 
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7.7.1 The availability of regulation 874 
7.7.2 Lack of enforcement of regulation 875 
7.8 Inspectors 876 
7.8.1 The qualifications of inspectors 877 
7.8.2 Number of inspectors 878 
7.8.3 Relationship between pharmacist and inspectors  879 
7.9 Insurance 880 
7.10 Patient filling system 881 
8 Commercial pressure 882 
 883 
 884 
 885 
 886 
 887 
 888 
 889 
 890 
 891 
 892 
 893 
 894 
 895 
 896 
 897 
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Coding index (Pharmacy users)  898 
1 Patient (related to the patient characteristics and others) 899 
 900 
1.1 Patient at risk of medication safety problems 901 
1.1.1  Patient with chronic diseases  902 
1.1.2 Patient with Allergies 903 
1.1.3 Patients with serious operations  904 
1.1.4 Patients with poly pharmacy 905 
1.1.5 Patients with kidney problems 906 
1.1.6 Patients with liver problems 907 
1.1.7 Gender 908 
1.1.7.1 Female 909 
1.1.7.1.1 Pregnant 910 
1.1.7.1.2 Hormones 911 
1.1.7.1.3 More prone to disease  912 
1.1.7.2 Male   913 
1.1.8 Age  914 
1.1.8.1 Paediatric 915 
1.1.8.2 Geriatric 916 
1.1.8.2.1 Bed ridden patients  917 
1.1.9 Education  918 
1.1.9.1 Patients 919 
1.1.9.2 Care givers  920 
 921 
1.2 Patients perceptions and believes 922 
1.2.1 The medication is safe if it is written in the package insert that it is safe  923 
1.2.2 Effective medicine are prescribed by the physician 924 
1.2.3 Medications prescribe by the physician are safe 925 
1.2.4 Illegal supply of medication by pharmacist are risky 926 
1.2.5 Community pharmacies are not safe  927 
1.2.6 Intervention of pharmacist is a must  928 
1.2.7 Antibiotics has to be used as directed  929 
1.2.8 Certain disease must be treated and others not important 930 
1.2.9 Pharmacies are shops, groceries  (for business) 931 
1.2.10 Patient risk perception 932 
1.2.10.1 Based on information provided 933 
1.2.10.2 According to setting (hospital vs. community pharmacy) 934 
1.2.10.3 Different routes are associated with different risks 935 
 936 
  937 
1.3 Patient /public awareness of medication safety  938 
1.3.1 Patient responsibility and role  939 
1.3.2 Patient awareness of regulations 940 
1.3.3 Awareness of the importance of the correct dosage form 941 
1.3.4 Awareness of the importance of the medication history 942 
1.3.5  Awareness about asking about allergies 943 
1.3.6 Awareness about the importance of asking about other medication 944 
 945 
1.4 Patient perception and attitude towards healthcare professionals roles 946 
1.4.1 Differentiate between health care professionals role 947 
1.4.2 Physicians 948 
1.4.2.1 Blame physician   949 
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1.4.2.2  Physician is always right  950 
1.4.3 Pharmacist 951 
1.4.3.1 Role of the pharmacist  952 
1.4.3.2 Perceive a positive role  953 
1.4.3.3 Perceive a negative role   954 
1.4.3.4 Based on nationality  955 
1.4.3.5 Blame pharmacist  956 
 957 
1.5 Patient behaviour  958 
1.5.1 Self medication  959 
1.5.2 Sharing medication 960 
1.5.3 Addiction/dependence problem 961 
1.5.4 Inappropriate medication use  962 
1.5.5 Do not follow instruction 963 
1.5.6 Patient pressure to supply medication  964 
1.5.7 Noncompliance  965 
1.5.8 Patients do not buy medication from pharmacist they do not know 966 
1.5.9 Patient test the pharmacist  967 
1.5.10 Patient do not want to decide for their selves  968 
1.5.11 Trust  969 
1.5.11.1 Patients trust pharmacist  970 
1.5.11.2 Based on knowledge 971 
1.5.11.3 Based on nationality 972 
 973 
2 Information and communication 974 
2.1 Sources of information  975 
2.1.1 Pharmacist  976 
2.1.2 Physician family, neighbours and friends 977 
2.1.3 Internet  978 
2.1.4 Package insert 979 
2.1.5 Advertisement  980 
2.1.6 Media  981 
 982 
2.2 Type of information requested  983 
2.2.1 What it is  984 
2.2.2 Direction of use 985 
2.2.3 Dose 986 
2.2.4 Dosage form 987 
2.2.5 What it is taken for 988 
2.2.6 Drug interaction  989 
2.2.7 Side effects  990 
2.2.8 Alternative 991 
2.2.9 Cost 992 
2.3 Quality of information provided 993 
2.3.1 Lack of information  994 
2.3.2 Wrong information 995 
2.3.3 Understandable information 996 
2.3.4 Not patient centred 997 
2.3.5 Conflicting information 998 
2.3.5.1 Between pharmacists 999 
2.3.5.2 Between pharmacist and physician 1000 
2.3.6 Communication between pharmacist and patient  1001 
2.3.6.1 Information exchange  1002 
2.3.6.1.1 Pharmacist start asking 1003 
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2.3.6.1.2 Patient start asking 1004 
2.3.6.2  Ask about the history 1005 
2.3.6.3 Allergic reaction  1006 
2.3.6.4 Other medication 1007 
2.3.6.5 Privacy  1008 
2.3.6.6 Time 1009 
2.3.6.7 Third party communicating patient information ( family member or other) 1010 
2.3.7 Communication between physician and patient  1011 
2.3.7.1 Insufficient information gathering from patient  1012 
 1013 
 1014 
3 Comparison between Saudi Arabia community pharmacy practice and other countries 1015 
3.1 Pharmacy setting 1016 
3.2 Pharmacist practice 1017 
3.3 Medication 1018 
 1019 
4 Medication  1020 
 1021 
4.1 Medication composition   1022 
4.2 Generic substitution 1023 
4.3 Illegal supply of medications 1024 
4.3.1 Factors that contribute to illegal supply of medication 1025 
4.3.2 Consequences of illegal supply  1026 
4.3.3 Illegal supply is safe 1027 
4.3.4 Illegal supply is risky 1028 
4.3.5 Medication that are illegally supplied  1029 
4.4 Safe Medication  1030 
4.4.1 Paracetamol products 1031 
4.4.2 Mebo 1032 
4.4.3 Otrivin  1033 
4.4.4 Nasonex 1034 
4.4.5 Cosmetics 1035 
4.4.6 Vitamin C 1036 
4.4.7 Aspirin 1037 
4.5 Risky medication 1038 
4.5.1 Contraceptives 1039 
4.5.2 Antibiotics  1040 
4.5.3 Cortisone 1041 
4.5.4 Asthma medication 1042 
4.5.5 Roaccutane 1043 
4.5.6 Whiting drugs  1044 
4.5.7 Psychotherapeutic agents 1045 
4.5.8 Thyroxin 1046 
4.5.9 Weight management agents 1047 
4.5.10 Creams 1048 
4.5.11 Multivitamins 1049 
4.5.12 Hormonal replacement therapy 1050 
4.5.13 Antihistamine 1051 
4.5.14 Medication for cough 1052 
4.5.15 Performance enhancing medication in sport 1053 
 1054 
4.6 Other related medication problems  1055 
4.6.1 Medications with unimproved indications 1056 
4.6.2 Sources of medication 1057 
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4.6.3 Availability of medication 1058 
4.6.4 Accessibility of medication 1059 
4.6.5 Quality of medication 1060 
4.6.6 Quantity of medication 1061 
4.6.7 Compounding  1062 
4.6.8 Counterfeit medications 1063 
4.6.9 Expiration date 1064 
4.6.10 Bar coding 1065 
4.6.11 Pricing 1066 
4.7 Herbal medication 1067 
4.8 Drug abuse 1068 
4.9 Drug misuse 1069 
4.10 Medication Storage 1070 
4.10.1 Dosage regimen 1071 
4.10.1.1 Dose  1072 
4.10.1.2 Dosage form 1073 
4.11 Medication related problem concerning patient outcome 1074 
4.11.1 Duplication of therapy 1075 
4.11.2 Adverse drug effects  1076 
4.11.3 Medication error 1077 
4.11.4 Allergy 1078 
4.11.5 Drug interaction 1079 
2.11.5.1 Consequences of drug interaction  1080 
 1081 
5 Pharmacist (related to the pharmacist characteristics and others) 1082 
5.1 Lack of knowledge  1083 
5.2 The quality of practice/unprofessional practice 1084 
5.3 Nationality 1085 
5.4 Working hours 1086 
5.5 Shortage of staff 1087 
5.6 Fraud certificate 1088 
5.7 unqualified pharmacist  1089 
5.8 Pharmacist busy 1090 
5.9 Pharmacist should be proactive  1091 
5.10 Ethics and morality  1092 
5.11 Stress  1093 
5.12 Salary 1094 
5.13 Commercial pressure  1095 
5.14 Primary role is a n information provider 1096 
5.15 Identify drug interaction 1097 
5.16 Pharmacovigilance 1098 
 1099 
6 Pharmacy  1100 
 1101 
6.1 Pharmacies are accessible  1102 
6.2 Sell everything  1103 
6.3 Source of medication when government cannot supply enough  1104 
6.4 Location and distribution 1105 
6.5 Pharmacy owners/managers 1106 
6.6 Other personal working in pharmacy  1107 
6.7 Pharmacy design and arrangement 1108 
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6.8 The use of technology  1109 
6.8.1 Patient databases  1110 
6.8.2 Drug information software’s 1111 
 1112 
7 Organisations and systems  1113 
7.1 Role of the Ministry of Health and other organisations 1114 
7.2 Regulation for pharmacy practice 1115 
7.2.1 The need for regulations 1116 
7.2.2 Licence and licensing 1117 
7.2.3 Punishment  1118 
7.2.4 Lack of enforcement of regulation 1119 
7.3 Insurance 1120 
7.3.1 The system 1121 
7.3.2 The affect of insurance on supply of medication 1122 
7.4 Variation between healthcare services  1123 
7.5 Pharmaceutical industry  1124 
7.6 Multiple health care providers  1125 
 1126 
8 Physician  1127 
8.1 Misdiagnosis  1128 
8.2 Physician prescribing behaviour 1129 
8.3 Prescribing error  1130 
8.4 Handwriting 1131 
8.5 Perception of patient that prescription prescribed by patients are safe 1132 
 1133 
 1134 
 1135 
 1136 
 1137 
 1138 
 1139 
 1140 
 1141 
 1142 
 1143 
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Appendix C 1144 
Selected quotes from the focus groups, illustrating examples of the themes that 1145 
emerged 1146 
 
Identified themes 
 
Human factor 
category 
 
Subthemes 
 
Quotes  
1. Commercialis
m and 
commercial 
pressure on 
community 
pharmacies in 
Saudi Arabia 
External 
factors 
 
Healthcare 
system role in 
commercialism 
 
“I mean the proportion of safety increased because the medical 
insurance makes everyone go to the doctor before they go to the 
pharmacist, and do not take the treatment directly from the 
pharmacy.” (I-4) 
 
 “Listen, the biggest problem of the medical insurance is that the 
doctors prescribe medicines they want to sell or will gain benefit 
from. The most important purpose of most pharmaceutical 
companies, not all, nowadays, is the sales nothing else, therefore 
they influence some doctors to prescribe their medicines regardless 
the patient needs it or not... Ok. This is the main problem of the 
insurance, because the patient does not pay high amount, therefore 
the prescription contains medicines that are over the patient's need, 
prescribed just to be sold, no more” (I-3) 
Organisational 
and 
management 
factors  
The role of 
Pharmacy 
owners and 
managers  
“Problems between you and the owner arise; he [the owner] asks what 
happened … [you] pay a penalty, close the pharmacy and your license 
is suspended. These problems face us and affect our work.” (CPG-4) 
 
Work 
environment 
Type of 
pharmacy and 
its effect on 
medication 
safety 
“We talk about the chain of pharmacy we spend a lot of time to train 
our pharmacists before going to be behind the counter to dispense 
medication…Chain of pharmacy or chain group it is easy to implement 
any regulations” (PG-2)  
 
 
“Street pharmacies [independent pharmacies] have more problems 
because the responsibility is like a burden on the pharmacist’s 
shoulders. He becomes a physician. On the other hand, when I am in a 
place [where] there is a clinic, half of my time is spent on prescriptions 
from the clinic, and the physician upstairs is doing his duty, writing the 
medicine that suits the patient and explaining to him the safety of the 
medicine. The clinic helps me, but when I work in a street pharmacy, I 
almost work alone, so I have to exert extra effort to explain to 
patients.” (I-4) 
 
 “…If you will find small pharmacies you will find most of the 
medication they survive on availability [availability of medication] in 
chain pharmacies they survive on the biggest bonuses they get.” (PG-
4) 
Pharmacist 
working hours 
 
 
“Often, pharmacists find themselves compelled to work in place of their 
colleagues for extra hours. For example, the average working hours 
are 15 or 17 hours [a day]. Seventeen hours is a [long time]. The 
maximum hours we have are 15 hours for certain periods in a month.”   
(CPG-1) 
 
“I don’t expect someone who is frustrated can produce…there should 
be controls regulating the rights and obligations of the pharmacist. I 
know someone working for the company (name). He tells me about 
what is happening he is responsible of choosing the best place to open 
a pharmacy and he schedules the pharmacist working schedule he says 
our profits are millions, do not blame the pharmacist they are 
frustrated.” (MPG-5) 
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 Low salaries  “I don’t expect anything from the pharmacist, because all pharmacists 
are frustrated and this is due to their low salaries and the nature of 
their work.  In a pharmacy, I noticed a pharmacist working in the 
middle of a hot day on Friday and he used to walk three or four 
kilometres.” (MPG-5) 
 
Team factors 
 
Physician 
prescribing 
behavior  
 “The medication is prescribed due to a commission, and this has 
resulted in a loss of confidence between us and physicians.” (MPG-7) 
 
“Listen, the biggest problem of the medical insurance is that the 
Doctors prescribe medicines they want to sell or will gain benefit 
from. The most important purpose of most pharmaceutical 
companies, not all, nowadays, is the sales nothing else, therefore 
they influence some doctors to prescribe their medicines regardless 
the patient needs it or not. Ok.”  (I-3) 
Task factors  
 
Patient 
counselling  
 “The pharmacists' required trait is honesty. He should be honest 
when giving an opinion or at least not give advice if his advice is for 
commercial purposes. His positive role is absent here.” (MPG-3) 
 
“My problem is always that when I go, they give me the best and the 
latest on the market, that is to say, they do not give me the one 
appropriate for me. The problem is that they do not try to learn 
whether it is appropriate or not.” (FPG-1) 
 
Generic 
substitution 
 
“He sometimes tells you about an alternative if one drug is expensive. I 
hear him saying, ‘its price is seventy, but there is an alternative that is 
only forty’.” (FPG-2) 
 
 “Price is not the issue, [it is to] prevent you [the patient] from going 
to other pharmacy” (FPG-5) 
 
“When I talk to him and he gives me options, [I think] I came to ask 
you! Why do you give me options? What do you like? [He asks] Do you 
want this medicine or is it ok with you if I give you this or this?' No, I 
want [him] to show me” (FPG-1)  
2. Illegal supply 
of 
prescription 
medication by 
pharmacist 
External 
factors 
  
“But in the past, we had same discussion by the way it is not logic that 
xxx dose not sell the medication without medications [means 
prescriptions] while my neighbour is selling without I will be broken 
and close my business. So, implementing in this time is very important 
as a chain of pharmacy owner and heading this kind of committee I 
think very willing we need some kind of cooperation from the Ministry 
of Health to encourage such way.  Of course, I believe always about 
penalties you need to implement something you need to do it the 
penalties if there is a punishment for one pharmacy dispensing that 
everybody will commit with that.” (PG-2) 
Individual 
factors: 
Pharmacist  
 
  
“We are pharmacists, we have certificates and we know what to 
dispense, but there are laws controlling us.” (CPG-3) 
 
“When you have a patient in front of you needing to be treated, it 
would be difficult, especially if the patient is poor and needs assistance, 
not to help him.” (CPG-4) 
 
“We are not only pharmacists, but also marketers. … I know why he 
wants the Liponex, whether he wants to sell or take four or five tablets 
… The same happens with the psychological medication … we may 
dispense it…Solving the problem of insomnia may not be that he 
cannot sleep, it may be depression, so we give him antidepressants like 
Liponex. A week prior to marriage anti-depressants may be needed, 
and we give Sirolex either for a man or a woman.” (CPG-3) 
 
“The CPs should not give medications without prescription … because 
they are risky.” (FPG-8) 
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3. Lack of 
enforcement 
of regulations  
External 
factors 
Regulations and 
regulators 
“We have three governing bodies in controlling the whole process 
[medication supply]: one controlling the medication SFDA, one 
controlling community pharmacy which is MOH, and one controlling 
the licensing pharmacist, I think either we have one governing body 
who is controlling the whole process and all effective collaborative 
efforts between these different agencies.” (PG-1) 
 
“I disagree with (PG-1) about what he mentioned about that 
community pharmacy practice should be under one umbrella. I think 
this is different because even in Europe the authority who is licensing 
for the pharmacist is different from the authority licensing for the 
pharmacy.” (PG-2) 
“The most important thing is the Ministry of Health, and it is 
important to inspect on the licenses of pharmacists. Does the 
pharmacist have a license or not? Does he have a card of the health 
certificate? There should be a follow-up on medicines in pharmacies. 
There are medicines sold which are trafficked. This would have to be 
controlled.” (I-3) 
 
Individual 
factors: 
Pharmacist  
 
Pharmacist 
adherence to 
law and 
regulations 
 
“No professional pharmacist will like to break the law...” (PG-4) 
 
 “… When someone comes requesting a combination, I make [prepare 
the medication as a compound] and hide it as if I am committing a 
crime.” (CPG-4) 
 
“... There is the regulation but they are playing with regulations...” (PG-
8)   
 
“Community pharmacy should have a sign state that no prescribed 
medication should be prescribed without a prescription from a 
physician we do have it in Arabic written everybody can read, ok. The 
problem community pharmacy pharmacists although there is a sign 
they are still selling medications without prescription.” (PG-1) 
 
 “There is no enforcement on pharmacists for example to label 
products although the law is saying you have to label products the law 
is saying you have to dispense with prescription … [moving his head] 
they are not doing. The only control that I can say fairly is the narcotic 
controlled medication.”  (PG-4) 
Medication 
factors  
 
Counterfeit 
medication as 
consequence  
“I have encountered a lot  of counterfeit products It is not medicines 
but other things, for example, herbs. Many medicines are from natural 
herbal components, but their origins or their producers are not known, 
and even there is nothing written on it, and not licensed by the Saudi 
Ministry of Health.” (I-3) 
 
“in Saudi Arabia counterfeit is not a major problem because the system 
we are going through and the good control of the port in general” (PG-
4) 
 
“I think the worst that we suffer regarding medications is fraud … they 
could be counterfeit” (FPG-9) 
4. Healthcare 
system in KSA 
External 
factors  
 
 
 
The fragmented 
healthcare 
system 
 “…And I remember one time one patient like he has two different 
insurance he went to two different doctors and get the same 
medication from the different insurance … so we also we need to 
connect all three [pharmacy, patient, health insurance system] 
together so we have a system for the insurance for this patient if he 
has two insurance so he will not abuse this insurance by getting the 
same kind of medication from different pharmacy or different 
hospitals.” (PG-5) 
 
Lack of patient 
database in 
community 
pharmacies 
 
“when PG-6 mentioned about the filing lets go even to institutions in 
the government you find some patients going to different hospitals 
with no common filing this is a problem starting from the beginning 
not from the community which is in the end of the road this is one of 
the problems I know some people going to different hospitals to get 
the same medication this is I think a problem. However, I am just 
wondering about it. This the time I think the MOH to upgrade the 
behaviour [to implement a filling system].” (PG-2) 
 
“He dispenses medication based on what information you provide 
him; nothing [is] documented” (MPG-7) 
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 Organizational 
and 
management 
factors  
Implementation 
of technology in 
community 
pharmacy 
“In America, there is a program contains the name of the medication 
to be dispensed drug-drug interaction. This system is good and 
increases the safety of medications and as to the problem of 
expiration” 
 
5. Patient 
medication 
taking behavior 
 Self-medication “CPG-2: I add the point of the medication, which needs monitoring at 
intervals such as vitamin D3 and it is of no use being taken randomly 
without measuring the levels at start. I see them may take the Swiss 
vitamin D3 (big clap) Each week he takes one bottle just because he 
thinks he is suffering from osteoporosis  
CPG-4: and this is what is common nowadays  
 CPG-1: what is common nowadays is that they suffer from vitamin D 
deficiency and then take it without taking baseline levels.” 
 
 “As for the medicine with severe risk that contains cortisone, most 
women especially here in the KSAuse cortisone [Steroids] for weight 
gain, […] Unfortunately, they take it a lot and repeatedly. They may 
take it monthly for many times.” (I- 3) 
 
“Yes, it is the core problem [self-medication]” (MPG-5) 
 
“Regrettably, the issue is the culture of the society, the easiness of 
obtaining some medications. No need to go far, in the United Arab 
Emirates, the antibiotic is taken through a prescription whereas in our 
country, you can take any kind of medications even it is controlled and 
even from private clinics. “(MPG-6) 
 
  
Sharing 
medication 
CPG-1: Cooperation, that is, I have a pharmacy at home  
CPG-5: as fruits in the refrigerator.  
Moderator: Well, does that mean all your medications are shared?  
CPG-1: No, not to this extent, may be antibiotic without 
exaggeration.  
Moderator: Could give me examples?  
CPG-5:  When I travel abroad I always have a packet of zithromyx 
and of course Fevadol, sprays and all medications that I will face a 
problem their not getting them. 
Moderator: do you share medications with the family, participant 4-
3 and participant CPG-4?  
CPG-4: Personally, I am careful with regard to medications, 
particularly antibiotics and I am careful not to be taken by my 
children unless for a compelling reason or according to specific 
instructions. That is, cautiousness with medications, specially, 
antibiotics. As to sharing, I don’t share may be Panadol or painkiller. 
 Adherence to 
medication 
 
“Yesterday, I was chatting with one of my friends. He said: while we 
were moving from house to house, we found a drawer in my mother’s 
room, when we open it; we found it full of medications. She used to 
bring medication from the hospital and place there so as not to use it.  
She admits only hypertension and cholesterol; in case of any other 
medical problems she hides its medication from her sons and 
daughters.” (MPG-6) 
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6. Patient trust in 
pharmacists 
  
 
 
 
  
“If working in the government sector, I think they could be honest as 
most of them are Saudis, with Saudi certificates, the foreigners you 
cannot know if they have qualification in the field or only salesmen […] 
certain places offer fraud certificates, but I do not know more details.” 
(FPG-1) 
 
“We have many cases … they do not know anything, sometimes they do 
not even know BID [to be taken two times a day].”   (PG-2) 
 
“Many thanks for him now because he refused to give medicine that 
was inappropriate … the pharmacist was honest; he seemed to be 
newly appointed.” (FPG-3) 
 
“Patients trust their doctor even if he made a mistake in something; 
patients never trust anybody else because they fully rely on the 
doctor.” (I-3)  
 
“I see if there is commitment and standards from the pharmacist. [This 
is] part sincerity. He asks you some questions to make you feel that he 
is careful, not just give and take some time, they just can get a member 
of staff to do that.” (MPG-2) 
 
7. Communication 
and information 
exchange 
 Patient–
pharmacist 
communication 
 
 
“The pharmacist should care about communication with the patient 
and not get bored questioning the patient. Despite the feeling that the 
patient does not want to be asked a lot of questions, the pharmacist 
should do what is best for him ethically. The goal is the patient’s 
benefit.” (CPG-1) 
 
“My work depends on communication with my patients.” (CPG-4) 
 
“I did not ask, but he was proactive. Just a little information about the 
medication and I will be thankful, as he is the specialist. I am sure that 
some of the medications have red lines [cautions]. Even if they are 
licensed, I need to be informed about the cautions on them.” (MPG-2) 
 
“I think education (being proactive) is not the role of the pharmacist. 
It is impossible to explain everything to everyone. If the patient asks, he 
should answer; if the patient does not ask, it is not the role of the 
pharmacist to explain.” (MPG-4) 
 Patient 
medication 
information 
source 
“I read a package insert with a lot of information warnings and side 
effects, I always get afraid … I immediately get my eye glasses and 
start reading… So even the words they use are harmful, especially 
when they say 1 in 100,000, some words hurt.”  (MPG-4) 
 Factors 
affecting 
communication 
exchange 
“The pharmacists they are male pharmacists, so the females most of 
them are sending their driver to get their medication they may not ask 
questions that can be a communication barrier. Many families send the 
driver to get the medication” (PG-3) 
 
“He gave him many options, maybe his child's age, I don't know, but he 
gave him options and explained [things] to him and gave him more 
time. I kept waiting. When it was my turn, he said to me, 'this is the 
best, so take it.” (FPG-1) 
 “…There is no chair in the reception, in the middle in front of him, a 
large space so he can put Strepsils and gum. You go abroad; there are 
chairs for waiting because he knows he will take some of my time to 
discuss information with the patient before me … no chairs for waiting, 
and if you wait, don’t expect them to tell you anything.” (MPG-5) 
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PG Professional Group 1147 
FPG Female Pharmacy Users Group 1148 
CPG Community Pharmacy Group 1149 
MPG Male Pharmacy Users Group 1150 
I       Interview participant 1151 
 1152 
  Type of 
information 
requested by 
patients from 
pharmacists 
Moderator: what are the most questions that you may ask?  
 MPG-2: the most important matter is to ask him about its side effects  
MPG-1: Correctly  
MPG-2:  what does the medication do? What is it composed of?  Should 
I continue? Should I continue the dose? May I reduce it? Is it taken 
when necessary?  
MPG-7: the important matter that I ask the pharmacist about is: for 
what problem is this medication taken for? That is in order to know 
whether the problem is actually a disease or not” 
  Information 
received from 
pharmacist 
information 
compared to 
information 
received from 
physician  
“The physician says, ‘Because of so and so this is no longer of benefit’, 
and when you go to the pharmacist, he gives another opinion. There is 
always a struggle inside of us about who to believe.”  (MPG-1) 
 
 “This is not the role of the pharmacist. If I take two prescriptions, it is 
not his role to tell me … to take this medication with that medication. 
It is not the responsibility of the pharmacist, not all pharmacists know 
drug interactions.” (MPG-4) 
 
The opposite opinion was also expressed: 
“Why did they study for five years?” (MPG-5) 
 
Team factors  
 
 
Communication 
between 
pharmacists and 
physicians 
“We also do not know how to communicate with physicians, secondly 
in order to communicate with him again we have to request his phone 
number. If I work at a pharmacy, which is far away from the clinic and 
try calling him my call is divert to an answer machine and they leave 
on hold the physician does not reply and you start from scratch to call 
again and stay on hold, you are keen to give the patient the right 
medication […] I think there is a safety problem with the prescription 
trying to communicate with him would be impossible.” (CPG-1) 
